Clinical Trial Detail

NCT ID NCT03646617
Title Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Abramson Cancer Center of the University of Pennsylvania
Indications

melanoma

Therapies

Ipilimumab + Nivolumab

Age Groups: senior adult

No variant requirements are available.